Literature DB >> 2759132

The metabolism and kinetics of 125I-labeled human intravenous IgG preparation (C-425) in rats and rabbits. I. Blood clearance, excretion into urine and feces, and brain uptake.

Y Kobayashi1, N Kobayashi, T Minaga, M Aihara, A Shigematsu.   

Abstract

The metabolism of intravenous human IgG preparation (C-425) was studied by the use of 125I-C-425 in rats and rabbits after intravenous injection of the compound particularly with regard to changes in the levels of radioactive compound or metabolites in the blood as a function of time as well as levels excreted in urine and feces. Brain uptake index of 125I-C-425 was estimated by a slightly modified Oldendorf's method. 125I-Polyglobin was used as the control compound. The half-life of blood clearance of 125I-C-425 radioactivity after the 2nd day was about 8 days in rats and about 5 days in rabbits, respectively. Within a relatively short period of 1 hour, a rapid decrease of blood concentration of radioactivity was recorded. This was due to the transfer of labelled compound from blood into the extravascular compartment. A high concentration of radioactivity in the blood was maintained for one week after intravenous injection of the labelled compound in both rats and in rabbits. Most of the radioactive compound or metabolites were excreted in the urine and relatively little in feces. Excretion in urine of rats reached about 22% for 125I-C-425 and about 17% for 125I-Polyglobin. The excretion rate slowed down over 24 hours. The total recovery rates in rats were about 40% for 125I-C-425 and 125I-Polyglobin and about 55% in rabbits for both drugs. The permeability through the blood-brain barrier was found to be negligible for both drugs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2759132     DOI: 10.1007/BF03190840

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  7 in total

1.  High specific activity iodination of gamma-globulin with iodine-131 monochloride.

Authors:  R W HELMKAMP; R L GOODLAND; W F BALE; I L SPAR; L E MUTSCHLER
Journal:  Cancer Res       Date:  1960-11       Impact factor: 12.701

2.  Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids.

Authors:  E J COHN; L E STRONG
Journal:  J Am Chem Soc       Date:  1946-03       Impact factor: 15.419

3.  Three generations of immunoglobulin G preparations for clinical use.

Authors:  J P McCue; R H Hein; R Tenold
Journal:  Rev Infect Dis       Date:  1986 Jul-Aug

4.  Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection.

Authors:  W H Oldendorf
Journal:  Am J Physiol       Date:  1971-12

5.  Microscale multisample two-dimensional electrophoresis of proteins in human serum, cerebrospinal fluid, and urine.

Authors:  T Manabe; E Hayama; T Okuyama
Journal:  Clin Chem       Date:  1982-04       Impact factor: 8.327

6.  A new preparation of modified immune serum globulin (human) suitable for intravenous administration. I. Standardization of the reduction and alkylation reaction.

Authors:  D D Schroeder; D L Tankersley; J L Lundblad
Journal:  Vox Sang       Date:  1981       Impact factor: 2.144

7.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

  7 in total
  2 in total

1.  The metabolism and kinetics of 125I-labeled intravenous human IgG preparation (C-425) in rats and rabbits. II. Excretion into bile, tissue distribution and placental permeability.

Authors:  Y Kobayashi; N Kobayashi; T Minaga; M Ogawa; A Shigematsu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jan-Mar       Impact factor: 2.441

2.  Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes.

Authors:  Bence Szikora; László Hiripi; Balázs Bender; Imre Kacskovics; Attila Iliás
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.